Recommendation for the use of newly introduced Tdap vaccine in Korea.
10.3345/kjp.2011.54.4.141
- Author:
Kyong Min CHOI
1
;
Kyung Hyo KIM
;
Yae Jean KIM
;
Jong Hyun KIM
;
Su Eun PARK
;
Hoan Jong LEE
;
Byung Wook EUN
;
Dae Sun JO
;
Eun Hwa CHOI
;
Young Jin HONG
Author Information
1. The Committee on Infectious Diseases, the Korean Pediatric Society, Korea. ckm2001@hanmail.net
- Publication Type:Review
- Keywords:
Pertussis;
Tdap vaccine
- MeSH:
Adolescent;
Adult;
Aged;
Communicable Diseases;
Cough;
Humans;
Incidence;
Infant;
Korea;
Ontario;
Pertussis Vaccine;
Whooping Cough
- From:Korean Journal of Pediatrics
2011;54(4):141-145
- CountryRepublic of Korea
- Language:English
-
Abstract:
Pertussis is an acute respiratory infection characterized by paroxysmal cough and inspiratory whoop for over 2 weeks. The incidence of pertussis has decreased markedly after the introduction of DTwP/DTaP vaccine, but the incidence of pertussis has increased steadily among young infant and among adolescents and adults in many countries. Td vaccine was used in this age group but the increase in pertussis has lead to the development of a Tdap vaccine. The Tdap vaccine is a Td vaccine with a pertussis vaccine added and is thought to decrease the incidence and transmission of pertussis in the respective age group. In Korea, two products are approved by the KOREA FOOD & DRUG ADMINISTRATION, which are ADACEL(TM) (Sanofi-Pasteur, Totonto, Ontario, Canada) and BOOSTRIX(R) (GlaxoSmithKline Biologicals, Rixensart, Belgium) for those aged between 11-64. This report summarizes the recommendations approved by the Committee on Infectious Diseases, the Korean Pediatric Society.
